New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers

The current screening-test for prostate cancer, affecting 10% of men worldwide, has a high false negative rate and a low true positive rate. A more reliable screening test is needed. Circulating-Tumor-Cells (CTC) provide a biomarker for early carcinogenesis, cancer progression and treatment effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ried, Karin, Tamanna, Tasnuva, Matthews, Sonja, Eng, Peter, Sali, Avni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192049/
https://www.ncbi.nlm.nih.gov/pubmed/32391268
http://dx.doi.org/10.3389/fonc.2020.00582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192049/
https://www.ncbi.nlm.nih.gov/pubmed/32391268
http://dx.doi.org/10.3389/fonc.2020.00582

Ejemplares similares